Centrexion's $67M Series D round to fund Phase 3 pain studies

Retrieved on: 2018-01-03 03:52:30

Tags for this article:

Medicine

Perception

Click the tags to see associated articles and topics

Centrexion's $67M Series D round to fund Phase 3 pain studies. View article details on hiswai:

Excerpt

<div>Boston-based Centrexion Therapeutics has finalized $67 million in Series D financing to fund upcoming phase 3 trials for its pain drug, CNTX-4975. Investors included <b>New Enterprise Associates</b>, which led the round, founding investor InterWest Partners, and several others – Quan Capital, ArrowMark ...</div>

Article found on:

View Original Article